SCHEMBL3548720

SCHEMBL3548720

C#CCOc1ccc(C(=S)N2CC[C@@H]2C(=O)NO)cc1C(F)(F)F

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 2/20 0.37
RXRA P19793 1/20 0.34
RXRB P28702 1/20 0.34
RXRG P48443 1/20 0.34
SSTR4 P31391 2/20 0.34
ADAM17 P78536 2/20 0.34
ALDH1A1 P00352 3/20 0.34
PKM P14618 1/20 0.34
POLB P06746 1/20 0.34
S1PR1 P21453 4/20 0.33
RBP4 P02753 1/20 0.33
TTR P02766 1/20 0.33
MMP1 P03956 1/20 0.33
SSTR1 P30872 1/20 0.32
SLC6A4 P31645 1/20 0.32
HRH3 Q9Y5N1 1/20 0.32
HSD11B1 P28845 1/20 0.32
GYS1 P13807 1/20 0.32
LRRK2 Q5S007 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3548717 1.00 SCN9A (0.37) SCN9ARXRARXRBRXRGSSTR4
SCHEMBL3548207 0.89 PDK2 (0.40) SCN9ARXRARXRBRXRGSSTR4
SCHEMBL3548205 0.89 PDK2 (0.40) SCN9ARXRARXRBRXRGSSTR4
SCHEMBL3545848 0.88 SCN9A (0.39) SCN9ARXRARXRBRXRGSSTR4
SCHEMBL3545850 0.88 SCN9A (0.39) SCN9ARXRARXRBRXRGSSTR4
SCHEMBL3547350 0.87 POLB (0.42) SCN9ARXRARXRBRXRGALDH1A1
SCHEMBL3547352 0.87 POLB (0.42) SCN9ARXRARXRBRXRGALDH1A1
SCHEMBL3554195 0.86 THRA (0.41) SCN9ARXRARXRBRXRGSSTR4
SCHEMBL3554198 0.86 THRA (0.41) SCN9ARXRARXRBRXRGSSTR4
SCHEMBL3539883 0.85 SCN9A (0.37) SCN9ARXRARXRBRXRGSSTR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7691843-B2 N-hydroxyamide derivatives possessing antibacterial activity PFIZER INC. (US) 2010-04-06 US claimed
US-20080058304-A1 N-hydroxyamide derivatives possessing antibacterial activity VICURON HOLDINGS LLC 2008-03-06 US claimed
US-7691843-B2 N-hydroxyamide derivatives possessing antibacterial activity PFIZER INC. (US) 2010-04-06 US disclosed
US-20080058304-A1 N-hydroxyamide derivatives possessing antibacterial activity VICURON HOLDINGS LLC 2008-03-06 US disclosed
EP-1539744-A4 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARM INC (US) 2007-06-06 EP disclosed
EP-1539744-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY Vicuron Pharmaceuticals, Inc. (US) 2005-06-15 EP disclosed
WO-2004007444-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS, INC. (US) 2004-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080058304-A1 N-hydroxyamide derivatives possessing antibacterial activity AMDHD2, OGA, ENGASE SCN9A 4080/4885RXRA 4524/4885RXRB 4684/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.